Photodynamic Therapy (PDT) for agerelated

Similar documents
Photodynamic therapy (PDT) for Central Serous Retinopathy (CSR)/ Polypoidal Choroidal Vasculopathy (PCV)

If you would like further information, please ask any of the staff at the clinic. They will be happy to help.

Treatment of wet macular degeneration by intravitreal injection with Ranibizumab (Lucentis) or Aflibercept (Eylea): Information and consent

Treatment of Age Related Macular Degeneration (AMD) by Intravitreal Injection

Age-Related Macular Degeneration (AMD)

Ophthamology Directorate. Eye Injection for Macular Disorders Information for Patients

What is Age-Related Macular Degeneration?

Intravitreal Injection

Age-related Macular Degeneration (AMD) treatment information

Patient Information Cataract Surgery

Treatment of Diabetic Macular Oedema by Intravitreal Injection with Ranibizumab (Lucentis)

Brampton Hurontario Street Brampton, ON L6Y 0P6

Preparing for laser treatment for diabetic retinopathy and maculopathy

Treatment of Retinal Vein Occlusion (RVO)

Introduction How the eye works

In all cases, a doctor will explain the procedure to you and answer any questions you may have.

INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION

Age-Related. macular degeneration.

RETINAL CONDITIONS RETINAL CONDITIONS

VISIONCARE S IMPLANTABLE MINIATURE TELESCOPE (by Dr. Isaac Lipshitz)

Cataract Surgery. Patient Information. How your care will be organised. Introduction

Important: Please read before your appointment

Information for patients

GENERAL INFORMATION DIABETIC EYE DISEASE

Diabetic Eye Disease

Diabetic Retinopathy A Presentation for the Public

A Patient s Guide to Diabetic Retinopathy

EYLEA. (aflibercept solution for injection) Patient Guide

Age-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis)

The Foundation WHAT IS THE RETINA?

Diabetes & Your Eyes

GHPI0100_06_10 Contact: Ophthalmology Review due: June What is a Cataract?

Understanding Diabetic Retinopathy

Cataracts in babies and children

Photofrin 75 mg Powder for solution for injection Porfimer sodium

Facts About Diabetic Eye Disease

Cataract and Cataract Surgery

The Human Eye. Cornea Iris. Pupil. Lens. Retina

Information for Patients undergoing Intravitreal Triamcinolone Acetonide (Kenalog) Injection

Fluorescein and Indocyanine Angiogram

Epiretinal membrane. What is an epiretinal membrane?

Screening saves sight. The importance of regular testing for diabetic retinopathy

AgePage. Aging And Your Eyes. Steps To Protect Your Eyesight

Patient Information Argon macular laser treatment Introduction

Diabetic retinopathy damage to the blood vessels in the retina. Cataract clouding of the eye s lens. Cataracts develop at an earlier age in people

UNDERSTAND MORE ABOUT UVEITIS UVEITIS

Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?

Eye injection treatment costs and rebates

Current indications for photodynamic therapy in medical retina practice

Information for Patients. Vitrectomy

Package leaflet: Information for the user. Visudyne 15 mg powder for solution for infusion verteporfin

Cataracts (1 of 7) What is a cataract? What can be done about a cataract? Lens

ILUVIEN 190 micrograms intravitreal implant in applicator (fluocinolone acetonide)

What is Fundus Fluorescein Angiography and Indocyanine Green Angiography?

DIABETIC RETINOPATHY


Patient information. Retinal Detachment Surgery St. Paul s Eye Unit PIF 024 V7

Information for patients considering cataract surgery Castleton Day Surgery Unit, Yeatman Hospital, Sherborne

Ophthalmology. Ophthalmology Services

Caregiver s guide to wet AMD

IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy

World Sight Day Case Studies. Mark Frost Screening Manager South East London DESP

Diabetic Retinopathy Information

Don t lose sight of the ones you love

Eye injection treatment costs and rebates

Retinal Detachment. Patient Information Leaflet. Ophthalmic Day Surgical Unit

Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre

AMD research at Moorfields

Photodynamic Therapy for Choroidal Neovascularization

Cataract. What is a Cataract?

The risks and benefits of cataract surgery

Information for Patients. Macular Hole

Fundus Fluorescein Angiography Indocyanine Green Angiography

Myopia and pathological myopia. Fundus Photo, Right Eye (OD)

Vitrectomy for diabetic vitreous haemorrhage

FEP Medical Policy Manual

Glaucoma Drainage Tube Surgery

Patient information Eylea treatment for diabetic macular oedema (DMO)

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description

Vision & Age - 40 s and 50 s Eyes

Age-Related Macular Degeneration

Cataract. What is a Cataract?

Diabetic Retinopathy Screening Programme

Cataract Surgery Patient Information

Rising to the Challenge of Satisfying Unmet Medical Needs. Back-of-the-eye. Main Back-of-the-Eye Diseases. Uveitis. Behcet s disease.

Fundus Fluorescein Angiogram (FFA) An information guide

Patient & Family Guide. Diabetes and the Eye. Aussi disponible en français : Le diabète et les yeux (FF )

Trabeculectomy (Glaucoma Drainage) Surgery

Description. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: December 7, 2011 Subject: Page: 1 of 23

Although photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *

Patient Information Brochure. Cataract

Diabetic Retinopathy

UVEITIS IN GENERAL. Information for patients UVEITIS CLINIC WHAT IS UVEITIS? MAIN CATEGORIES OF UVEITIS

PATIENT INFORMATION LEAFLET. PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM OZURDEX, dexamethasone 700 μg intravitreal implant

RVO RETINAL VEIN OCCLUSION

NHS Diabetic Eye Screening Programme

Uveitis / Iritis. Introduction. Other formats

Intravitreal Injections for Wet Age Related Macular Degeneration

Cataract = opaque lens

Vitrectomy for diabetic vitreous haemorrhage

Transcription:

Page 1 of 5 Photodynamic Therapy (PDT) for agerelated eye conditions Introduction This leaflet gives you information about Photodynamic Therapy (PDT) for the age--related eye conditions macular degeneration and Central Serous Chorioretinopathy (CSCR). The aim of this leaflet is to explain what to expect at all stages of the treatment and to answer some of the questions you may have. What is Age-related Macular Degeneration? The macula is the centre part of the retina at the back of the eye. Many different conditions can damage the macula and lead to sight problems. Age--related Macular Degeneration (AMD) is a condition which occurs later in life. There are 2 types of Age--related Macular Degeneration, usually known as wet AMD and dry AMD. PDT has been shown to be effective in treating a number of types of wet AMD, in particular Choroidal Neovascular Membrane (CNV) and Polypoidal Choroidal Vasculopathy (PCV). Wet AMD is caused by the development of abnormal blood vessels at the macula. These abnormal blood vessels cause fluid leakage, bleeding and scarring at the macula which can lead to sudden sight loss which cannot be cured. What is Central Serous Chorioretinopathy (CSCR)? CSCR is a condition where there is a build--up of fluid at the back of the eye, causing single or multiple areas of retinal detachment. Reference No. GHPI0574_02_17 Department Ophthalmology Review due February 2020 What is Photodynamic Therapy (PDT)? PDT slows down or stops the development of abnormal blood vessels at the macula. The treatment aims to save the useful vision you have left, but you should not expect the treatment to improve it.

Page 2 of 5 A light activated medicine called Visudyne is used for PDT and is given by an injection into a vein in your arm. This medicine collects in the abnormal blood vessels in your eye, where it is activated using a gentle red laser light to treat your AMD. The aim is to close the abnormal blood vessels without harming other tissue at the back of the eye. You may need up to 5 treatments over a period of 2 years. PDT can sometimes be used for treating other conditions in the eye and can be used to treat other conditions in the body. Before treatment When you arrive at the Eye Clinic, your vision will be tested and drops put into your eyes to enlarge your pupils. The drops will cause your sight to be blurred for a period of time so you must not drive to or from your appointment. We may carry out some tests such as a repeat Fluorescein/Indocyanine Green Angiogram to help us assess your condition. Your eyes will also be examined by an eye specialist. Your height and weight will be measured so that we know how much Visudyne to use. During treatment A specially trained nurse will give you an injection of Visudyne through a flexible tube (cannula) in your arm, which will take about 10 minutes. A nurse will stay with you while you have this Anaesthetic drops will be put in your eye before laser A contact lens will be placed on your eye for the laser treatment which helps the laser light to be focused on the affected area at the back of your eye. We will then carry out the laser This involves shining a special red laser light into your eye for 83 seconds. The laser treatment is not painful. Your vision is likely to be blurred for a few hours after treatment because of the dilating drops.

Page 3 of 5 Possible rare side effects of PDT The Visudyne can leak out of the vein at the injection site which can cause pain, swelling, inflammation or bleeding. About 2 in 100 of patients experience some back pain while the Visudyne is being given, which can be helped by moving around (such as walking a few paces) until the pain wears off. Some patients experience a temporary mild blurring of vision following You must not drive or use machinery until the blurring wears off. Between 1 to 4 in 100 patients experience a severe, but usually temporary, decrease in vision in the treated eye following Please tell the doctor before your treatment if you have experienced any of the following: If you have had a severe reaction to previous injections into a vein (intravenous) If you have a history of allergies If you have porphyria or severe liver disease After treatment PDT will cause your skin and eyes to become more sensitive to light. You must avoid direct sunlight and bright indoor lights for 48 hours after Ordinary indoor light is not harmful, but you should avoid halogen lights, including halogen light bulbs in the house and outside and car head lights. You should not have any surgery or dental work for 48 hours after Tanning salons should also be avoided for 48 hours after If you are near a window, make sure that the curtains or blinds are closed, this includes skylights. Do not rely on UV sunscreens to protect against light sensitivity, they will not be effective. Wear protective clothing, hat and sunglasses. Please bring (or wear) the following items with you to the Eye Clinic: Wide--brimmed hat Dark sun--glasses

Page 4 of 5 Clothing that will fully cover your arms and legs Socks and shoes. Follow up appointments You will have an appointment to check your progress around 1 to 2 months after PDT If needed, Fluorescein/Indocyanine Green Angiography and PDT will be repeated as before. Benefits of the procedure PDT can slow or stop the deterioration in your vision due to wet age--related macular degeneration. There is some evidence that photodynamic therapy is a helpful treatment for central serous chorioretinopathy (CSCR). As mentioned before, the aim of PDT treatment is to save the useful vision you have left, but you should not expect the treatment to improve it Other procedures Several studies have shown that there is real benefit in having PDT treatment along with the current gold standard treatment for wet AMD (intravitreal anti--vegf agents, for example Eylea and Lucentis ) in terms of getting rid of polyps, saving the vision you have left and reducing the need for ongoing Please ask your consultant if you would like further information on studies about PDT and other treatments discussed in this leaflet. If you decide not to have PDT treatment you will carry on with intravitreal Anti--VEGF agents as needed, and you will be given advice about how to make best use of the sight you have left. If you have any questions about your treatment which has not been covered by this leaflet please ask a member of the medical or nursing team in the Eye Clinic.

Page 5 of 5 Contact information Eye Outpatient Clinic Gloucestershire Royal Hospital Tel: 0300 422 8358 Monday to Thursday, 9:00am to 5:30pm, Friday, 9:00am to 1:00pm Casualty Eyeline Tel: 0300 422 3578 Calls are answered by a nurse between 9:00am and 5:30pm, Monday to Thursday and 9:00am to 1:00pm on Fridays. At all other times your call will be diverted to the operator who will contact the on call eye doctor Content reviewed: February 2017